Valneva Stock Rebounds and Climbs Over 28% in One Month
After the previous decline, Valneva regains ground in this first September session, contrary to the SBF 120 which is slightly down. The movement occurs in a context of high monthly volatility, while the stock accumulates over 28% over the last thirty days despite a week still in the red.
A Rebound That Consolidates Position Above Short-Term Moving Averages
Valneva gains 1.99% in the session, at €2.76, ranking among the strongest gainers of the SBF 120 in a declining market (the index loses 0.44%). The increase brings the stock above its 20-day MA at €2.67 (a gap of +3.45%) and well above its 50-day MA at €2.39 (a gap of +15.56%), which outlines a positive technical configuration in the short term. In contrast, the 200-day MA at €3.20 remains well above the current price, at a gap of 13.69%, a ceiling that has not yet been approached.
The RSI at 55 remains in neutral territory, with no overbought signal, which leaves room before the upward momentum encounters technical compression. The next resistance is identified at €3.07, representing an upside potential of around 11% from the current price.
A Fundamentally Strained File, Despite Receding Short Positions
On fundamentals, Valneva remains a stock under structural pressure: the first half 2026 financial statements published on August 13 showed a widened net loss of €63.3 million, in a context of declining product sales and unfavorable trends in travel vaccines. The group nonetheless confirmed its annual targets upon this publication. One potentially bullish element remains pending: the EMA agreed in August to examine the marketing authorization application file for the candidate vaccine against Lyme disease, developed in partnership with Pfizer, without the regulatory outcome being known at this stage. On the short-selling side, three funds cumulate 2.70% of capital sold short, according to available declarations, down 0.78 points over one month (compared to 3.48% thirty days ago).
This reduction reflects a gradual easing of bearish bets following a high plateau, without meaning their disappearance. The analysts' opinion on the stock remains worth monitoring in this context of marked monthly rebound, against the backdrop of a half-year balance sheet still in deficit. Over one year, the stock is still down 27.77%, which illustrates the extent of the distance remaining to recover to previous year's levels.
